Celgene's disclosures about ozanimod this week spur analysts' fears of a lengthy delay for a key drug
Researchers for Celgene $CELG turned up at the American Academy of Neurology meeting this week with some news about the multiple sclerosis drug ozanimod that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
